"The increase is driven by the optimisation of production processes, the recent initiation of production at BioNTech#39;s Marburg, Germany facility, regulatory approval for six dose vials, and the expansion of our manufacturing and supplier network," BioNTech said in a statement.BioNTech raises COVID vaccine output goal to 2.5 billion doses
"The increase is driven by the optimisation of production processes, the recent initiation of production at BioNTech#39;s Marburg, Germany facility, regulatory approval for six dose vials, and the expansion of our manufacturing and supplier network," BioNTech said in a statement.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment